| Home | E-Submission | Sitemap | Contact Us |  
Cancer Research and Treatment > Volume 35(2); 2003 > Article
Cancer Research and Treatment 2003;35(2): 123-129. doi: https://doi.org/10.4143/crt.2003.35.2.123
Infusional 5-Fluorouracil, Leucovorin and Docetaxel in Advanced Gastric Cancer
Yong Tai Kim, Joo Hyuk Sohn, So Hun Kim, Sun Young Rha, Chul Kim, Jae Kyung Roh, Byung Soo Kim, Woo Ick Jang, Hyun Cheol Chung
1Cancer Metastasis Reserch Center, Yonsei University Collegeof Medicine, Seoul, Korea.
2Yonsei Cancer Center, Yonsei University College of Medicine,Seoul, Korea. unchung8@yumc.yonsei.ac.kr
3Division of Hemato-Oncology, Yonsei University College ofMedicine, Seoul, Korea.
4Department of Internal Medicine, Yonsei University Collegeof Medicine, Seoul, Korea.
5Brain Korea 21 Project for Medical Science, YonseiUniversity College of Medicine, Seoul, Korea.
6Lilly Korea, Ltd., Seoul, Korea.
  Published online: April 30, 2003.
This study was performed to estimate the response rate and toxicity of a combination chemotherapy, which included infusional 5-Fluorouracil, Leucovorin and Docetaxel in the treatment of patients with an advanced gastric carcinoma.
Twenty two advanced gastric cancer patients, with a bidimensionally measurable or an evaluable disease, were enrolled in this study. The patients received a 5-fluorouracil 1, 000 mg/m2 intravenous (IV) 24 hour infusion (Day 1~3), leucovorin 20 mg/m2 (Day 1~3) and docetaxel 75 mg/m2 intravenously (Day 2) every 3 weeks.
The overall response rate was 45.0%. The median duration of response was 10.0 weeks (range: 4~24), the median time to response was 8 weeks (range: 8~20) the median time to progression was 30.0 weeks (95% CI: 16.3~43.2) and the median overall survival duration was 36.0 weeks (95% CI: 1.7~70.2). The median cumulative dose of 5-fluorouracil were 316.2 mg/m2/week and docetaxel was 23.9 mg/m2/week. WHO grade III, IV neutropenia, thromocytopenia and anemia occurred in 50.0%, 4.5% and 4.5% of patients, respectively. There were no occurrence of WHO grade III and IV nausea, vomiting, mucositis, conspitation, diarrhea, or neurotoxicity.
This chemotherapy regimen, including infusional 5-fluorouracil, leucovorin and docetaxel was an active agent against advanced gastric cancer patients, especially for previous chemotherapy naive patients.
Key words: Stomach neoplasm;Combination Chemotherapy;Infusional 5-FU;Leucovorin;Docetaxel
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association.                 Developed in M2PI